Skip to content

Psilocybin research published in 2023

Page 8 of 19: studies 141 to 160 of 375, newest first. Back to the psilocybin overview

Studies

Exploring the relationship between mental health, drug use, personality, and attitudes towards psilocybin-assisted therapy

Journal of Psychedelic Studies August 21, 2023 Benjamin M. Ross, James T. Neill 6 citations

Abstract Background Psilocybin, the psychoactive compound in magic mushrooms, is increasingly discussed in terms of its psychotherapeutic potential; however, little is known about community attitudes towards psilocybin assisted therapy (PAT). Aims To address the question: What are the public's attitudes towards psilocybin and psilocybin-assisted therapy? And what factors explain these...

Seasonal Variation of Use of Common Psychedelics and Party Drugs Among Nightclub/Festival Attendees in New York City

Journal of Psychoactive Drugs August 21, 2023 Caroline Rutherford, Austin Le, Joseph J Palamar et al. 2 citations

Few epidemiological studies have focused on seasonal variation in the use of common psychedelics and party drugs among nightclub and festival attendees, typically those who attend electronic dance music (EDM) events. We sought to determine whether the use of different drug types varies seasonally within this population. Across 15 seasons from summer 2017 through fall 2022, we surveyed 3,935...

A Proposal to Study the Safety and Efficacy of Psilocybe cubensis in Preclinical and Clinical Studies as a Therapeutic Alternative for Major Depressive Disorder

Journal of Psychoactive Drugs August 18, 2023 Raul Escamilla, María Eva González-Trujano, Jesús M. González Mariscal et al. 7 citations

The pharmacological treatment of depression consists of taking antidepressant drugs for prolonged periods; its modest therapeutic effect can often be associated with significant adverse effects, while its discontinuation can lead to relapses. Psilocybin is today a novel and breakthrough therapy for major depression. It is a natural alkaloid in Psilocybe mushrooms, which are endemic to Mexico....

DOI: 10.1080/02791072.2023.2246459 (opens in new tab) Psychedelic therapy Major depression Psilocybe mushrooms Psychedelic medicine +3

Medical Students' Attitudes and Beliefs Toward Psilocybin: Does Terminology and Personal Experience with Psychedelics Matter?

Psychedelic Medicine August 18, 2023 Claudia Lex, Antonio F. Pagán, Jair C Soares et al. 9 citations

Background: Psilocybin and psychedelic-assisted therapy (PAT) have gained renewed interest due to recent findings that PAT can enhance therapeutic outcomes. In 2019, the U.S. Food & Drug Administration (FDA) approved breakthrough therapy status to psilocybin for the treatment of depression, but PAT has yet to be approved as a therapeutic treatment for mental health disorders. Should the FDA...

Psilocybin‐assisted psychotherapy for treatment‐resistant depression: Which psychotherapy?

International Journal of Mental Health Nursing August 17, 2023 Marie Crowe, Jenni Manuel, Dave Carlyle et al. 6 citations

Abstract This perspective paper explores the choice of psychotherapy for psilocybin‐assisted psychotherapy for treatment‐resistant depression. There is evidence to support the use of some psychotherapies in treating ‘treatment‐resistant’ depression, and emerging evidence for the efficacy of psilocybin. The next step which is the focus of this paper is to identify psychotherapies that are both...

Developing a Direct Observation Measure of Therapeutic Connection in Psilocybin-Assisted Therapy: A Feasibility Study

Journal of Palliative Medicine August 17, 2023 Robert Gramling, Emily Bennett, Keith Curtis et al. 6 citations

Context: Measuring therapeutic connection during psilocybin-assisted therapy is essential to understand underlying mechanisms, inform training, and guide quality improvement. Purpose: To evaluate the feasibility of directly observing indicators of therapeutic connection during psilocybin administration encounters. Methods: We evaluated audio and video data from a recent clinical trial for...

“Diversity makes the richness of humanity”: the emergence of mental imagery after self-reported psilocybin mushrooms intake in an autistic woman with “blind imagination” (aphantasia): a 1-year retrospective case report

August 16, 2023 Kevin Rebecchi 2 citations preprint

This retrospective case report explores the impact of psilocybin mushroom intake on the emergence of mental imagery in an autistic woman with aphantasia. Aphantasia refers to the inability to generate visual mental images, which can significantly affect individuals' experiences and cognitive processes. The case study focuses on a 34-year-old autistic woman who had been living with aphantasia...

The use of psilocybin in the treatment of psychiatric disorders – review

Journal of Education, Health and Sport August 15, 2023 Justyna Woźniak, Rafał Bogacz, Magdalena Gaik et al.

Introduction: The word “psychedelic” derives from the Greek language and can be loosely translated as “mind manifesting” which is to convey that these substances allow the mind to unleash its hidden potential. Psilocybin is considered to be a “classic psychedelic” and is most commonly found in the form of so-called “magic mushrooms”. Due to its unique properties psilocybin has been used during...

The risk of chronic psychedelic and MDMA microdosing for valvular heart disease

Journal of Psychopharmacology August 12, 2023 Michael Tagen, Daniel Mantuani, Alex Holstein et al. 39 citations

Psychedelic microdosing is the practice of taking very low doses of psychedelic substances, typically over a longer period of time. The long-term safety of chronic microdosing is relatively uncharacterized, but valvular heart disease (VHD) has been proposed as a potential risk due to activation of the serotonin 5-HT 2B receptor. However, this risk has not yet been comprehensively assessed. This...

Psilocybin's Emerging Role in Combating Depressive Disorder

Journal of Education, Health and Sport August 8, 2023 Anna Jaremek, Joanna Kępa, Norbert Kandefer et al.

In this review paper, we delve into the potential applicability of psilocybin - a naturally synthesized psychedelic substance found within select species of fungi, as a prospective avenue for depression treatment. Depression, a widespread psychological malady affecting countless individuals across the globe, often proves stubborn against existing treatment modalities, necessitating exploration...

“But the reality is it's happening”: A qualitative study of eating disorder providers about psilocybin‐assisted psychotherapy

International Journal of Eating Disorders August 8, 2023 Maxine Boyd, Joshua Woolley, Amanda E. Downey et al. 7 citations

Abstract Objective This study invited providers who care for patients with eating disorders to inform engagement, communication, and collaboration with psilocybin‐assisted psychotherapy interventions. Method Medical and mental health providers who treat patients with eating disorders were recruited via professional referral networks and participant driven sampling from across California to...

DOI: 10.1002/eat.24041 (opens in new tab) Psilocybin Eating disorders Psychological intervention Psychotherapist +2

Psilocybin-assisted therapy for depression: A systematic review and dose-response meta-analysis of human studies

European Neuropsychopharmacology August 7, 2023 Natacha Perez, Florent Langlest, Luc Mallet et al. 85 citations

Psilocybin is increasingly studied for its antidepressant effect, but its optimal dosage for depression remains unclear. We conducted a systematic review and a dose-response meta-analysis to find the optimal dosage of psilocybin to reduce depression scores. Following our protocol (CRD 42022220190) multiple electronic databases were searched from their inception until February 2023, to identify...

A Brief Review on the Potential of Psychedelics for Treating Alzheimer’s Disease and Related Depression

International Journal of Molecular Sciences August 7, 2023 Alexander Pilozzi, Simmie Foster, David Mischoulon et al. 16 citations

Alzheimer’s disease (AD), the most common form of senile dementia, is poised to place an even greater societal and healthcare burden as the population ages. With few treatment options for the symptomatic relief of the disease and its unknown etiopathology, more research into AD is urgently needed. Psychedelic drugs target AD-related psychological pathology and symptoms such as depression. Using...

Prevalence of psilocybin use in vaping and associated factors: a study among amphetamine-type stimulants (ATS) use disorder in Malaysia

Journal of Addictive Diseases August 4, 2023 Ruzmayuddin Mamat, Rusdi Abd Rashid, Baharudin Ibrahim et al. 2 citations

Psilocybin in vaping is growing among ATS users and across all populations. Unfortunately, knowledge regarding the long-term effects on health is limited. Further studies should highlight the harmful effects of psilocybin and the potential risk of psilocybin vaping among the younger population.

Slouching towards engagement: interactions between people using psychedelics naturalistically and their healthcare providers

Frontiers in Psychiatry August 4, 2023 Kasey Cox, Cody Weston, Moss Herberholz et al.

Introduction There is substantial public interest in psychedelics as potential treatments for psychiatric conditions. However, most psychedelics are criminalized under federal law in the USA, so it is unclear whether use occurs with clinical support. Our objective was to assess whether naturalistic psychedelic use occurs with clinical support, interactions between those using psychedelics and...

DOI: 10.3389/fpsyt.2023.1224551 (opens in new tab) Psilocybin Confidentiality Health care Disconnection +2

Transient Elevation of Plasma Glucocorticoids Supports Psilocybin-Induced Anxiolysis in Mice

ACS Pharmacology & Translational Science August 2, 2023 Zarmeen Zahid, Zhen Zheng, N. Jones et al. 50 citations

While correlations between drug-induced cortisol elevation, self-reported anxiety, and treatment outcomes have been reported for human studies during psilocybin-assisted psychotherapy, the mechanistic relationship between psychedelic-associated alterations in plasma glucocorticoid responses and the time course of anxious responsiveness remains unclear. Using rodents, both time-bound...

DOI: 10.1021/acsptsci.3c00123 (opens in new tab) Psilocybin Anxiolytic Corticosterone Antagonist +5

How does psilocybin therapy work? An exploration of experiential avoidance as a putative mechanism of change.

Journal of Affective Disorders August 1, 2023 Richard J. Zeifman, Anne C Wagner, Candice M Monson et al. 56 citations

Psilocybin therapy is receiving attention as a mental health intervention with transdiagnostic potential. In line with psychotherapeutic research, qualitative research has highlighted the role of reductions in experiential avoidance (and increases in connectedness) within psilocybin therapy. However, no quantitative research has examined experiential avoidance as a mechanism underlying...

On the mushrooming reports of “quiet quitting”: Employees’ lifetime psilocybin use predicts their overtime hours worked

Journal of Psychoactive Drugs July 31, 2023 Benjamin A. Korman 8 citations

Despite the recent and sharp rise in psychedelic research, few studies have investigated how classic psychedelic use relates to employees' work-related outcomes. This is surprising given that the increased use, decriminalization, and legalization of classic psychedelics in the United States (U.S.) has the potential to impact both employees and their organizations. Addressing this gap, the...

DOI: 10.1080/02791072.2023.2242358 (opens in new tab) Psilocybin Overtime Legalization Decriminalization +3

“Why would you open someone’s brain up?” Lived experience insights inform a psilocybin-assisted psychotherapy treatment manual for body image disturbance

Research Square July 27, 2023 Claire Finkelstein, Olivia Soha, Alana Roy et al. 2 citations preprint

Abstract Background: Body Image Disturbance (BID) is the distorted experience of one’s body. BID presents a risk for the onset, maintenance and relapse of body dysmorphic disorder and eating disorders, including anorexia nervosa (AN). Current treatments tend to focus on the cognitive and behavioural aspects while overlooking the perceptual symptoms and BID frequently persists beyond physical...

DOI: 10.21203/rs.3.rs-3189970/v1 (opens in new tab) Full text (opens in new tab) Thematic analysis Psychological intervention Psychotherapist Psychoeducation +5